(18.97.9.172)
[ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2018, Volume : 11, Issue : 9
First page : ( 3897) Last page : ( 3899)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2018.00714.X

The Biochemical Response of Acetyl Cholinesterasein Prostate Cancer in relation to the Environment

Asaad Jaleel Ibrahim1, Al-Mamoori Ayad M. J.2, Shukri Hussein Mahmood3, Sail Asmaa Ibrahim1, Ahmed Enas Shehab1, Nadhmi Aya4

1Biotechnology Research Center, AL-Nahrin University, Iraq

2Biology Dept., College of Science, University of Babylon, Iraq

3Biotechnology College, AL-Nahrin University, Iraq

4Biochemistry Departments, Ottawa University, Canada

Corresponding Author E-mail:

Online published on 20 December, 2018.

Abstract

Acetylcholinesterase (ACHE) is an enzyme. Its main extracellular function isto hydrolyze the Acetylcholine to choline and acetate, and maintain the correct levels of Acetylcholine in the body and according to the Environmental Factors. Another function for (ACHE) in intra cellular compartment is to stimulate cell proliferation and apoptosis. In this study, we try to investigate the (ACHE) and prostate cancer overlapping to get new diagnostic markerand/or treatment for prostate cancer. Results: There is no significant difference in serum (ACHE) of patients with prostate cancer (12.90 ± 4.17ng/ml), in comparison to control group (9.0 ± 1.78 ng/ml), (p>0.05). But there is significant increase in serum (ACHE) incases with high grade prostate cancer with Gleason grade more than 7, (11.90 ± 2.11ng/ml), in comparison to lower grade prostate cancerwith Gleason grade less than 7, and control group (10.20 ± 2.20and 9.0 ± 1.78ng/ml respectively), (p<0.05). Conclusion: Because of thevariation inthe level of serum (ACHE) in patients with prostate cancer, this marker can't consider as prognostic protein for diagnosis ofprostate cancer. However further prospective studies are recommended to demonstrate its role in the diagnosis, grading and elimination of the tumor.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
861,815,132 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.